CASTLE BIOSCIENCES INC
CASTLE BIOSCIENCES INC
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 62 | 64 | 117 | 86 | 82 | 90 | 120 | 95 | 86 | 83 | 99 | 91 | |||||
Available For Sale Securities Debt Securities Curr… | - | - | - | - | - | - | - | 185 | 174 | 156 | 144 | 139 | |||||
Marketable Securities Current | 205 | 198 | 183 | 202 | 194 | 185 | 173 | - | - | - | 144 | - | |||||
Accounts Receivable Net Current | 48 | 42 | 43 | 49 | 52 | 56 | 51 | 50 | 46 | 43 | 38 | 37 | |||||
Inventory Net | 11 | 10 | 10 | 9 | 8 | 7 | 8 | 7 | 8 | 8 | 8 | 6 | |||||
Prepaid Expense And Other Assets Current | 15 | 14 | 8 | 12 | 12 | 11 | 8 | 8 | 7 | 6 | 6 | 7 | |||||
Assets Current | 341 | 329 | 361 | 358 | 349 | 349 | 360 | 345 | 320 | 296 | 296 | 280 | |||||
Marketable Securities Noncurrent | - | - | - | - | - | 6 | - | - | - | - | - | - | |||||
Accounts Receivable Net Noncurrent | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Property Plant And Equipment And Finance Lease Rig… | 105 | 101 | 97 | 85 | 74 | 55 | 51 | 44 | 39 | 33 | 25 | 22 | |||||
Operating Lease Right Of Use Asset | 14 | 14 | 15 | 15 | 16 | 11 | 12 | 12 | 12 | 12 | 12 | 12 | |||||
Intangible Assets Net Including Goodwill | 95 | 97 | 100 | 102 | 104 | 78 | 106 | 111 | 113 | 115 | 117 | 120 | |||||
Other Assets Noncurrent | 4 | 4 | 4 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 1 | 2 | |||||
Assets | 561 | 548 | 579 | 563 | 545 | 502 | 531 | 515 | 487 | 459 | 453 | 436 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 10 | 15 | 19 | 12 | 13 | 9 | 7 | 7 | 10 | 9 | 10 | 7 | |||||
Employee Related Liabilities Current | 27 | 19 | 38 | 32 | 25 | 18 | 33 | 28 | 21 | 15 | 29 | 22 | |||||
Asset Acquisition Contingent Consideration Liabili… | 2 | 1 | 1 | 1 | 1 | - | 0 | - | - | - | - | - | |||||
Operating Lease Liability Current | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | |||||
Long Term Debt Current | 3 | 2 | 0 | 0 | 2 | 1 | 0 | - | - | - | 0 | - | |||||
Other Accrued Liabilities Current | 14 | 11 | 9 | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 6 | |||||
Liabilities Current | 57 | 49 | 69 | 55 | 51 | 37 | 49 | 44 | 39 | 32 | 48 | 36 | |||||
Long Term Debt Noncurrent | 7 | 8 | 10 | 10 | 8 | 9 | 10 | 10 | 10 | 10 | 0 | - | |||||
Asset Acquisition Contingent Consideration Liabili… | 0 | 2 | 2 | 2 | 2 | - | 0 | - | - | - | - | - | |||||
Operating Lease Liability Noncurrent | 25 | 25 | 25 | 25 | 25 | 14 | 14 | 15 | 14 | 14 | 14 | 13 | |||||
Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | |||||
Deferred Income Tax Liabilities Net | 2 | 2 | 2 | 3 | 3 | 1 | 2 | 4 | 0 | 0 | 0 | 0 | |||||
Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Liabilities | 91 | 86 | 108 | 96 | 89 | 61 | 75 | 74 | 63 | 56 | 62 | 50 | |||||
Stockholders Equity | |||||||||||||||||
Preferred Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 711 | 700 | 695 | 689 | 677 | 666 | 656 | 650 | 636 | 623 | 609 | 602 | |||||
Retained Earnings Accumulated Deficit | -241 | -239 | -224 | -222 | -221 | -226 | -200 | -210 | -212 | -221 | -218 | -216 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | |||||
Stockholders Equity | 470 | 461 | 471 | 467 | 455 | 440 | 456 | 441 | 424 | 402 | 391 | 386 | |||||
Liabilities And Stockholders Equity | 561 | 548 | 579 | 563 | 545 | 502 | 531 | 515 | 487 | 459 | 453 | 436 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |||||
Common Stock Shares Issued | 31 | 30 | 30 | 29 | 29 | 29 | 28 | 28 | 28 | 28 | 27 | 27 | |||||
Shares Outstanding | 31 | 30 | 30 | 29 | 29 | 29 | 28 | 28 | 28 | 28 | 27 | 27 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.83% | -1.82% | -0.26% | - | - | - | - | - | - | - | - | - |
| 2025 | -14.83% | 8.53% | -14.29% | 56.72% | 48.24% | 59.99% | 53.71% | 51.58% | 62.52% | -21.58% | -21.42% | -39.99% |
| 2024 | 6.70% | -6.35% | -12.78% | 35.79% | 27.51% | 43.57% | -9.99% | -20.24% | -21.40% | -18.83% | -14.91% | -33.74% |
| 2023 | - | - | - | 10.96% | -1.61% | -23.76% | 19.40% | 29.91% | 15.08% | -16.89% | -20.83% | -0.62% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 6.04 | 6.75 | 5.26 | 6.47 | 6.85 | 9.37 | 7.29 | 7.78 | 8.12 | 9.25 | 6.20 | 7.70 | |||||
| Quick Ratio | 5.58 | 6.23 | 4.99 | 6.09 | 6.45 | 8.89 | 6.97 | 7.45 | 7.75 | 8.82 | 5.90 | 7.34 | |||||
| Working Capital | 284.59M | 280.14M | 292.42M | 302.26M | 297.78M | 312.11M | 310.76M | 300.48M | 280.95M | 263.82M | 247.97M | 243.30M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.19 | 0.19 | 0.23 | 0.20 | 0.20 | 0.14 | 0.17 | 0.17 | 0.15 | 0.14 | 0.16 | 0.13 | |||||
| Interest Coverage TTM | -85.62 | -163.99 | -497.79 | -226.84 | -69.64 | -23.77 | 15.03 | -2.13 | -54.71 | -1,996.48 | -6,179.73 | -6,550.08 | |||||
| Debt Ratio | 0.16 | 0.16 | 0.19 | 0.17 | 0.16 | 0.12 | 0.14 | 0.14 | 0.13 | 0.12 | 0.14 | 0.12 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.65 | 0.65 | 0.62 | 0.64 | 0.67 | 0.72 | 0.67 | 0.66 | 0.63 | 0.57 | 0.49 | 0.43 | |||||
| Days Sales Outstanding TTM | 51.41 | 52.95 | 50.15 | 52.99 | 51.81 | 52.08 | 49.20 | 51.06 | 49.05 | 51.26 | 51.30 | 56.88 | |||||
| Receivables Turnover TTM | 7.10 | 6.89 | 7.28 | 6.89 | 7.05 | 7.01 | 7.42 | 7.15 | 7.44 | 7.12 | 7.12 | 6.42 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.64 | -0.43 | -0.83 | -0.42 | -0.32 | -0.18 | 0.62 | 0.21 | -0.11 | -1.12 | -2.14 | -2.81 | |||||
| Free Cash Flow Per Share TTM | -0.02 | 0.15 | 0.98 | 0.87 | 1.19 | 1.46 | 1.32 | 1.24 | 0.73 | -0.23 | -0.72 | -1.56 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 77.26% | 77.88% | 79.37% | 79.94% | 81.00% | 81.94% | 81.87% | 81.90% | 81.86% | 80.58% | 79.53% | 78.08% | |||||
| Operating Profit Margin TTM | -8.99% | -9.79% | -12.44% | -10.17% | -6.66% | -3.97% | 2.61% | -0.33% | -5.48% | -16.72% | -30.93% | -44.35% | |||||
| Net Profit Margin TTM | -5.43% | -3.78% | -7.02% | -3.56% | -2.73% | -1.46% | 5.49% | 1.95% | -1.08% | -12.28% | -26.15% | -39.32% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 3.18% | -2.06% | 3.66% | 10.15% | 20.40% | 38.43% | 51.09% | 62.43% | 71.67% | 64.71% | 60.38% | 55.17% | |||||
| Net Income Growth (1Y) | 105.10% | 153.15% | -232.41% | -301.42% | 205.45% | -83.54% | -131.75% | -108.05% | -96.51% | -57.06% | -14.41% | 42.59% | |||||
| EPS Growth (1Y) | 95.08% | 142.31% | -226.88% | -292.87% | 192.06% | -84.19% | -130.64% | -107.76% | -96.63% | -58.43% | -16.79% | 39.84% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -37.34 | -57.18 | -46.67 | -54.10 | -62.37 | -112.99 | 40.57 | 130.70 | -194.21 | -19.77 | -10.06 | -6.00 | |||||
| P/B TTM | 1.54 | 1.59 | 2.39 | 1.42 | 1.30 | 1.30 | 1.62 | 1.80 | 1.42 | 1.51 | 1.48 | 1.17 | |||||
| P/S TTM | 2.03 | 2.16 | 3.28 | 1.93 | 1.71 | 1.65 | 2.23 | 2.55 | 2.09 | 2.43 | 2.63 | 2.36 | |||||
| Market Cap | 725.02M | 733.77M | 1.13B | 661.99M | 590.42M | 572.75M | 740.23M | 794.00M | 601.85M | 608.79M | 578.39M | 453.23M | |||||
| Enterprise Value | 672.98M | 680.08M | 1.02B | 586.49M | 518.23M | 493.10M | 630.54M | 709.05M | 526.29M | 535.84M | 479.57M | 362.00M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -489.00K | 4.52M | 28.33M | 25.38M | 34.54M | 41.75M | 36.54M | 34.54M | 20.13M | -6.46M | -19.25M | -41.83M | |||||
| Net Debt | -52.04M | -53.70M | -106.67M | -75.51M | -72.19M | -79.66M | -109.69M | -84.94M | -75.56M | -72.95M | -98.82M | -91.22M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
CASTLE BIOSCIENCES INC (CSTL) — SEC Financial Statements & Analysis
CASTLE BIOSCIENCES INC (CSTL) is a services-medical laboratories company, incorporated in DE. CASTLE BIOSCIENCES INC trades on Nasdaq as: CSTL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CASTLE BIOSCIENCES INC reported a 3.18% year-over-year revenue growth, a Gross Profit Margin of 77.26% (TTM), a Debt-to-Equity ratio of 0.19x, a Price-to-Sales (P/S) ratio of 2.03x (TTM), a Price-to-Book (P/B) ratio of 1.54x (TTM), at a market cap of $725.02M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 3.18%
- Gross Profit Margin TTM
- 77.26%
- Debt To Equity
- 0.19x
- P/S TTM
- 2.03x
- P/B TTM
- 1.54x
- Market Cap
- $725.02M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CASTLE BIOSCIENCES INC in?
CASTLE BIOSCIENCES INC (CSTL) operates in the Services-Medical Laboratories industry.
What is CSTL's market cap?
CASTLE BIOSCIENCES INC (CSTL) has a market capitalization of $725.02M as of 2026-06-30.
What exchange does CSTL trade on?
CASTLE BIOSCIENCES INC (CSTL) trades on the Nasdaq.
Where is CASTLE BIOSCIENCES INC incorporated?
CASTLE BIOSCIENCES INC is incorporated in DE.